asthma

[Proceedings of the National Academy of Sciences of the United States of America] The authors sought β2AR agonists for treating obstructive lung diseases such as asthma, in which this receptor relaxed airway smooth muscle cells and opened airways.

[European Journal of Pharmacology] Transient receptor potential vanilloid 2 (TRPV2) may represent a novel biomarker for asthma in children; meanwhile, TRPV1 and TRPV4 seem to be essential contributors to the development and exacerbations of asthma.

[Molecular Immunology] Researchers investigated whether Omarigliptin possessed a beneficial effect against LPS-induced injuries in human BEAS-2B bronchial epithelial cells.

[PLoS One] Researchers tested three classes of drugs commonly prescribed to treat asthma for their ability to promote barrier function using a cell culture model of virus-induced airway epithelial barrier disruption.

[British Journal of Pharmacology] Investigators developed C391, a potent proteinase-activated receptor-2 (PAR2) antagonist effective in blocking peptidomimetic- and trypsin-induced PAR2 signaling in vitro as well as reducing inflammatory PAR2-associated pain in vivo.

[Cellular & Molecular Immunology] Increased Metrnβ effectively blocked the development of airway hyperreactivity and decreased inflammatory cell airway infiltration and type 2 cytokine production, which was associated with downregulated dendritic-mediated adaptive immune responses.